September 29 Sep 29
2021
12:00 PM - 1:00 PM
Wednesday Wed
ZOOM

Pathology Grand Rounds

Presenting Guest Lecturer: Samuel Aparicio
"Drug resistance and novel targeting approaches for genomically unstable breast and ovarian cancers"

Samuel Aparicio, BM, BCh, PhD, FRCPath, FRSC

Nan & Lorraine Robertson Chair in Breast Cancer Research
Canada Research Chair in Molecular Oncology, UBC
Distinguished Scientist and Head, Department of Breast & Molecular Oncology, BC Cancer, part of the Provincial Health Services Authority Professor, UBC Department of Pathology & Laboratory Medicine
UBC Distinguished University Scholar
Fellow, Royal Society of Canada, Life Science Division

The Pathology Grand Rounds is open to those affiliated with Stanford University Medical Center and invited guests only. The objective is to increase knowledge in the field of Pathology. There is no commercial support received for this course unless otherwise specified.

Per COVID restrictions Grand Rounds are now available via ZOOM until further notice. Please contact Roomana Patel at roomana@stanford.edu or 650-725-9352 for ZOOM login information.

This lecture is hosted by Stanford Pathology Faculty

About the Speaker

Dr. Samuel Aparicio, BM, BCh, PhD, FRCPath, FRSC

Professor, UBC
Distinguished Scientist, Department Head, Molecular Oncology, BCCA

Affiliation(s): BC Cancer/BCRI

The Aparicio lab studies the genomic and phenotypic behaviour of breast and other cancers. Integrating leading edge technologies with patient-derived xenograft models of cancer, this research is working to better understand how cancer clones evolve and to identify novel strategies for cancer treatment and predictors of response.

Dr. Aparicio’s research program encompasses the fields of cancer genomics, cancer evolution, single cell biology, mouse genetic models, high throughput screens, small molecule chemical probe development and translational breast cancer research. His work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed, and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype (TNBC). Dr. Aparicio is also working to develop quantitative measures of clonal fitness in patients, including methods for single cell genome sequencing and PDX models of human cancer. He collaborates widely with other groups, with current projects including the genomic and biochemical analysis of lymphoma, ovarian cancer, and several rare pediatric cancers. He was a co-founder of Paradigm Therapeutics (now, Takeda Cambridge) and currently Canexia Health.